
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Register with Psychiatric Times to receive these exclusive pdfs: "2010 Staff Salary Survey: Regional Data" and "What Should You Pay Staff?" Register Today - It's Free!
Receive Exclusive PDFs
September 23, 2010
Register with Psychiatric Times to receive these exclusive pdfs: "2010 Staff Salary Survey: Regional Data" and "What Should You Pay Staff?" Register Today - It's Free!




